Cétirizine 1 % + minoxidil 5 % face à Minoxidil 5 % seul (placebo ajouté)

and great increase = excellent. Group 1 showed excellent response in 16 patients, very good in 7, good in 2 and no change in one patient, while in group 2, 17 patients showed excellent response, 6 were very good, 4 were good and one patient showed no change. Fisher’s exact showed statistically insignificant difference between groups.

Citation complémentaire (significativite)

(N = 27) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* P-value (t × g)* 70.11 ± 12.99 70.25 ± 11.88 70.20 ± 12.05 0.998a 0.665b 29.88 ± 12.99 29.74 ± 11.88 29.79 ± 12.05 0.998a 0.665b 107.87 ± 28.63 133.44 ± 35.73 197.36 ± 43.07 < 0.0005*a 0.549b 46.92 ± 24.03 59.08 ± 35.73 85.90 ± 40.86 < 0.0005*a 0.724b 3.21 ± 2.31 3.02 ± 1.86 3.19 ± 2.54 0.916 a 0.601b 46.05 ± 8.93 47.17 ± 9.38 45.12 ± 9.35 0.345a 0.843b 1.56 ± 0.25 1.73 ± 0.34 1.60 ± 0.28 0.062a 0.965b

Bassiouny EA, El-Samanoudy SI, Abbassi MM et al.. Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. Archives of Dermatological Research 2023, DOI 10.1007/s00403-022-02512-2. Citation sous licence CC-BY-4.0.

and great increase = excellent. Group 1 showed excellent response in 16 patients, very good in 7, good in 2 and no change in one patient, while in group 2, 17 patients showed excellent response, 6 were very good, 4 were good and one patient showed no change. Fisher’s exact showed statistically insignificant difference between groups.

Citation complémentaire (significativite)

(N = 27) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* P-value (t × g)* 70.11 ± 12.99 70.25 ± 11.88 70.20 ± 12.05 0.998a 0.665b 29.88 ± 12.99 29.74 ± 11.88 29.79 ± 12.05 0.998a 0.665b 107.87 ± 28.63 133.44 ± 35.73 197.36 ± 43.07 < 0.0005*a 0.549b 46.92 ± 24.03 59.08 ± 35.73 85.90 ± 40.86 < 0.0005*a 0.724b 3.21 ± 2.31 3.02 ± 1.86 3.19 ± 2.54 0.916 a 0.601b 46.05 ± 8.93 47.17 ± 9.38 45.12 ± 9.35 0.345a 0.843b 1.56 ± 0.25 1.73 ± 0.34 1.60 ± 0.28 0.062a 0.965b

Bassiouny EA, El-Samanoudy SI, Abbassi MM et al.. Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. Archives of Dermatological Research 2023, DOI 10.1007/s00403-022-02512-2. Citation sous licence CC-BY-4.0.

Trichoscopic Cetirizine + minoxidil group parameter (N = 26) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* Terminal hair 64.73 ± 15.63 67.71 ± 14.24 66.76 ± 13.44 0.355a percentage (%) Vellus hair per- 35.26 ± 15.63 32.28 ± 14.24 33.23 ± 13.44 0.355a centage (%) Terminal hair 97.62 ± 32.89 120.45 ± 36.73 177.43 ± 43.15 < 0.0005*a density/cm2 Vellus hair 52.77 ± 23.91 58.12 ± 28.29 90.98 ± 42.77 < 0.0005*a density/cm2 Terminal:vellus 2.84 ± 3.39 3.21 ± 3.46 2.99 ± 3.60 0.378 a Average 42.29 ± 10.06 43.91 ± 8.53 42.37 ± 7.97 0.217a thickness(µm) Average number 1.49 ± 0.22 1.68 ± 0.34 1.53 ± 0.21 0.007*a of hairs/ fol- licular unit * Level of significance P ˂ 0.05 a One-way RM-ANOVA (Time effect (t)) at P ˂ 0.05 b Mixed RM-ANOVA (time*group interaction (t × g)) at P ˂ 0.05 1 3 Archives of Dermatological Research (2023) 315:1293–1304 assessor (mean ranks: group 1 = 29.40 and N = 26, group

Citation complémentaire (significativite)

(N = 27) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* P-value (t × g)* 70.11 ± 12.99 70.25 ± 11.88 70.20 ± 12.05 0.998a 0.665b 29.88 ± 12.99 29.74 ± 11.88 29.79 ± 12.05 0.998a 0.665b 107.87 ± 28.63 133.44 ± 35.73 197.36 ± 43.07 < 0.0005*a 0.549b 46.92 ± 24.03 59.08 ± 35.73 85.90 ± 40.86 < 0.0005*a 0.724b 3.21 ± 2.31 3.02 ± 1.86 3.19 ± 2.54 0.916 a 0.601b 46.05 ± 8.93 47.17 ± 9.38 45.12 ± 9.35 0.345a 0.843b 1.56 ± 0.25 1.73 ± 0.34 1.60 ± 0.28 0.062a 0.965b

Bassiouny EA, El-Samanoudy SI, Abbassi MM et al.. Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. Archives of Dermatological Research 2023, DOI 10.1007/s00403-022-02512-2. Citation sous licence CC-BY-4.0.

(N = 27) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* P-value (t × g)* 70.11 ± 12.99 70.25 ± 11.88 70.20 ± 12.05 0.998a 0.665b 29.88 ± 12.99 29.74 ± 11.88 29.79 ± 12.05 0.998a 0.665b 107.87 ± 28.63 133.44 ± 35.73 197.36 ± 43.07 < 0.0005*a 0.549b 46.92 ± 24.03 59.08 ± 35.73 85.90 ± 40.86 < 0.0005*a 0.724b 3.21 ± 2.31 3.02 ± 1.86 3.19 ± 2.54 0.916 a 0.601b 46.05 ± 8.93 47.17 ± 9.38 45.12 ± 9.35 0.345a 0.843b

Citation complémentaire (significativite)

(N = 27) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* P-value (t × g)* 70.11 ± 12.99 70.25 ± 11.88 70.20 ± 12.05 0.998a 0.665b 29.88 ± 12.99 29.74 ± 11.88 29.79 ± 12.05 0.998a 0.665b 107.87 ± 28.63 133.44 ± 35.73 197.36 ± 43.07 < 0.0005*a 0.549b 46.92 ± 24.03 59.08 ± 35.73 85.90 ± 40.86 < 0.0005*a 0.724b 3.21 ± 2.31 3.02 ± 1.86 3.19 ± 2.54 0.916 a 0.601b 46.05 ± 8.93 47.17 ± 9.38 45.12 ± 9.35 0.345a 0.843b 1.56 ± 0.25 1.73 ± 0.34 1.60 ± 0.28 0.062a 0.965b

Bassiouny EA, El-Samanoudy SI, Abbassi MM et al.. Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. Archives of Dermatological Research 2023, DOI 10.1007/s00403-022-02512-2. Citation sous licence CC-BY-4.0.

Trichoscopic Cetirizine + minoxidil group parameter (N = 26) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* Terminal hair 64.73 ± 15.63 67.71 ± 14.24 66.76 ± 13.44 0.355a percentage (%) Vellus hair per- 35.26 ± 15.63 32.28 ± 14.24 33.23 ± 13.44 0.355a centage (%) Terminal hair 97.62 ± 32.89 120.45 ± 36.73 177.43 ± 43.15 < 0.0005*a density/cm2 Vellus hair 52.77 ± 23.91 58.12 ± 28.29 90.98 ± 42.77 < 0.0005*a density/cm2 Terminal:vellus 2.84 ± 3.39 3.21 ± 3.46 2.99 ± 3.60 0.378 a Average 42.29 ± 10.06 43.91 ± 8.53 42.37 ± 7.97 0.217a thickness(µm) Average number 1.49 ± 0.22 1.68 ± 0.34 1.53 ± 0.21 0.007*a of hairs/ fol- licular unit * Level of significance P ˂ 0.05 a One-way RM-ANOVA (Time effect (t)) at P ˂ 0.05 b Mixed RM-ANOVA (time*group interaction (t × g)) at P ˂ 0.05 1 3 Archives of Dermatological Research (2023) 315:1293–1304 assessor (mean ranks: group 1 = 29.40 and N = 26, group

Citation complémentaire (significativite)

(N = 27) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* P-value (t × g)* 70.11 ± 12.99 70.25 ± 11.88 70.20 ± 12.05 0.998a 0.665b 29.88 ± 12.99 29.74 ± 11.88 29.79 ± 12.05 0.998a 0.665b 107.87 ± 28.63 133.44 ± 35.73 197.36 ± 43.07 < 0.0005*a 0.549b 46.92 ± 24.03 59.08 ± 35.73 85.90 ± 40.86 < 0.0005*a 0.724b 3.21 ± 2.31 3.02 ± 1.86 3.19 ± 2.54 0.916 a 0.601b 46.05 ± 8.93 47.17 ± 9.38 45.12 ± 9.35 0.345a 0.843b 1.56 ± 0.25 1.73 ± 0.34 1.60 ± 0.28 0.062a 0.965b

Bassiouny EA, El-Samanoudy SI, Abbassi MM et al.. Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. Archives of Dermatological Research 2023, DOI 10.1007/s00403-022-02512-2. Citation sous licence CC-BY-4.0.

(N = 27) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* P-value (t × g)* 70.11 ± 12.99 70.25 ± 11.88 70.20 ± 12.05 0.998a 0.665b 29.88 ± 12.99 29.74 ± 11.88 29.79 ± 12.05 0.998a 0.665b 107.87 ± 28.63 133.44 ± 35.73 197.36 ± 43.07 < 0.0005*a 0.549b 46.92 ± 24.03 59.08 ± 35.73 85.90 ± 40.86 < 0.0005*a 0.724b 3.21 ± 2.31 3.02 ± 1.86 3.19 ± 2.54 0.916 a 0.601b 46.05 ± 8.93 47.17 ± 9.38 45.12 ± 9.35 0.345a 0.843b

Citation complémentaire (significativite)

(N = 27) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* P-value (t × g)* 70.11 ± 12.99 70.25 ± 11.88 70.20 ± 12.05 0.998a 0.665b 29.88 ± 12.99 29.74 ± 11.88 29.79 ± 12.05 0.998a 0.665b 107.87 ± 28.63 133.44 ± 35.73 197.36 ± 43.07 < 0.0005*a 0.549b 46.92 ± 24.03 59.08 ± 35.73 85.90 ± 40.86 < 0.0005*a 0.724b 3.21 ± 2.31 3.02 ± 1.86 3.19 ± 2.54 0.916 a 0.601b 46.05 ± 8.93 47.17 ± 9.38 45.12 ± 9.35 0.345a 0.843b 1.56 ± 0.25 1.73 ± 0.34 1.60 ± 0.28 0.062a 0.965b

Bassiouny EA, El-Samanoudy SI, Abbassi MM et al.. Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. Archives of Dermatological Research 2023, DOI 10.1007/s00403-022-02512-2. Citation sous licence CC-BY-4.0.

Trichoscopic Cetirizine + minoxidil group parameter (N = 26) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* Terminal hair 64.73 ± 15.63 67.71 ± 14.24 66.76 ± 13.44 0.355a percentage (%) Vellus hair per- 35.26 ± 15.63 32.28 ± 14.24 33.23 ± 13.44 0.355a centage (%) Terminal hair 97.62 ± 32.89 120.45 ± 36.73 177.43 ± 43.15 < 0.0005*a density/cm2 Vellus hair 52.77 ± 23.91 58.12 ± 28.29 90.98 ± 42.77 < 0.0005*a density/cm2 Terminal:vellus 2.84 ± 3.39 3.21 ± 3.46 2.99 ± 3.60 0.378 a Average 42.29 ± 10.06 43.91 ± 8.53 42.37 ± 7.97 0.217a thickness(µm) Average number 1.49 ± 0.22 1.68 ± 0.34 1.53 ± 0.21 0.007*a of hairs/ fol- licular unit * Level of significance P ˂ 0.05 a One-way RM-ANOVA (Time effect (t)) at P ˂ 0.05 b Mixed RM-ANOVA (time*group interaction (t × g)) at P ˂ 0.05 1 3 Archives of Dermatological Research (2023) 315:1293–1304 assessor (mean ranks: group 1 = 29.40 and N = 26, group

Citation complémentaire (significativite)

(N = 27) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* P-value (t × g)* 70.11 ± 12.99 70.25 ± 11.88 70.20 ± 12.05 0.998a 0.665b 29.88 ± 12.99 29.74 ± 11.88 29.79 ± 12.05 0.998a 0.665b 107.87 ± 28.63 133.44 ± 35.73 197.36 ± 43.07 < 0.0005*a 0.549b 46.92 ± 24.03 59.08 ± 35.73 85.90 ± 40.86 < 0.0005*a 0.724b 3.21 ± 2.31 3.02 ± 1.86 3.19 ± 2.54 0.916 a 0.601b 46.05 ± 8.93 47.17 ± 9.38 45.12 ± 9.35 0.345a 0.843b 1.56 ± 0.25 1.73 ± 0.34 1.60 ± 0.28 0.062a 0.965b

Bassiouny EA, El-Samanoudy SI, Abbassi MM et al.. Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. Archives of Dermatological Research 2023, DOI 10.1007/s00403-022-02512-2. Citation sous licence CC-BY-4.0.

(N = 27) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* P-value (t × g)* 70.11 ± 12.99 70.25 ± 11.88 70.20 ± 12.05 0.998a 0.665b 29.88 ± 12.99 29.74 ± 11.88 29.79 ± 12.05 0.998a 0.665b 107.87 ± 28.63 133.44 ± 35.73 197.36 ± 43.07 < 0.0005*a 0.549b 46.92 ± 24.03 59.08 ± 35.73 85.90 ± 40.86 < 0.0005*a 0.724b 3.21 ± 2.31 3.02 ± 1.86 3.19 ± 2.54 0.916 a 0.601b 46.05 ± 8.93 47.17 ± 9.38 45.12 ± 9.35 0.345a 0.843b

Citation complémentaire (significativite)

(N = 27) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* P-value (t × g)* 70.11 ± 12.99 70.25 ± 11.88 70.20 ± 12.05 0.998a 0.665b 29.88 ± 12.99 29.74 ± 11.88 29.79 ± 12.05 0.998a 0.665b 107.87 ± 28.63 133.44 ± 35.73 197.36 ± 43.07 < 0.0005*a 0.549b 46.92 ± 24.03 59.08 ± 35.73 85.90 ± 40.86 < 0.0005*a 0.724b 3.21 ± 2.31 3.02 ± 1.86 3.19 ± 2.54 0.916 a 0.601b 46.05 ± 8.93 47.17 ± 9.38 45.12 ± 9.35 0.345a 0.843b 1.56 ± 0.25 1.73 ± 0.34 1.60 ± 0.28 0.062a 0.965b

Bassiouny EA, El-Samanoudy SI, Abbassi MM et al.. Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. Archives of Dermatological Research 2023, DOI 10.1007/s00403-022-02512-2. Citation sous licence CC-BY-4.0.

Trichoscopic Cetirizine + minoxidil group parameter (N = 26) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* Terminal hair 64.73 ± 15.63 67.71 ± 14.24 66.76 ± 13.44 0.355a percentage (%) Vellus hair per- 35.26 ± 15.63 32.28 ± 14.24 33.23 ± 13.44 0.355a centage (%) Terminal hair 97.62 ± 32.89 120.45 ± 36.73 177.43 ± 43.15 < 0.0005*a density/cm2 Vellus hair 52.77 ± 23.91 58.12 ± 28.29 90.98 ± 42.77 < 0.0005*a density/cm2 Terminal:vellus 2.84 ± 3.39 3.21 ± 3.46 2.99 ± 3.60 0.378 a Average 42.29 ± 10.06 43.91 ± 8.53 42.37 ± 7.97 0.217a thickness(µm) Average number 1.49 ± 0.22 1.68 ± 0.34 1.53 ± 0.21 0.007*a of hairs/ fol- licular unit * Level of significance P ˂ 0.05 a One-way RM-ANOVA (Time effect (t)) at P ˂ 0.05 b Mixed RM-ANOVA (time*group interaction (t × g)) at P ˂ 0.05 1 3 Archives of Dermatological Research (2023) 315:1293–1304 assessor (mean ranks: group 1 = 29.40 and N = 26, group

Citation complémentaire (significativite)

(N = 27) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* P-value (t × g)* 70.11 ± 12.99 70.25 ± 11.88 70.20 ± 12.05 0.998a 0.665b 29.88 ± 12.99 29.74 ± 11.88 29.79 ± 12.05 0.998a 0.665b 107.87 ± 28.63 133.44 ± 35.73 197.36 ± 43.07 < 0.0005*a 0.549b 46.92 ± 24.03 59.08 ± 35.73 85.90 ± 40.86 < 0.0005*a 0.724b 3.21 ± 2.31 3.02 ± 1.86 3.19 ± 2.54 0.916 a 0.601b 46.05 ± 8.93 47.17 ± 9.38 45.12 ± 9.35 0.345a 0.843b 1.56 ± 0.25 1.73 ± 0.34 1.60 ± 0.28 0.062a 0.965b

Bassiouny EA, El-Samanoudy SI, Abbassi MM et al.. Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. Archives of Dermatological Research 2023, DOI 10.1007/s00403-022-02512-2. Citation sous licence CC-BY-4.0.

(N = 27) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* P-value (t × g)* 70.11 ± 12.99 70.25 ± 11.88 70.20 ± 12.05 0.998a 0.665b 29.88 ± 12.99 29.74 ± 11.88 29.79 ± 12.05 0.998a 0.665b 107.87 ± 28.63 133.44 ± 35.73 197.36 ± 43.07 < 0.0005*a 0.549b 46.92 ± 24.03 59.08 ± 35.73 85.90 ± 40.86 < 0.0005*a 0.724b 3.21 ± 2.31 3.02 ± 1.86 3.19 ± 2.54 0.916 a 0.601b 46.05 ± 8.93 47.17 ± 9.38 45.12 ± 9.35 0.345a 0.843b

Citation complémentaire (significativite)

(N = 27) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* P-value (t × g)* 70.11 ± 12.99 70.25 ± 11.88 70.20 ± 12.05 0.998a 0.665b 29.88 ± 12.99 29.74 ± 11.88 29.79 ± 12.05 0.998a 0.665b 107.87 ± 28.63 133.44 ± 35.73 197.36 ± 43.07 < 0.0005*a 0.549b 46.92 ± 24.03 59.08 ± 35.73 85.90 ± 40.86 < 0.0005*a 0.724b 3.21 ± 2.31 3.02 ± 1.86 3.19 ± 2.54 0.916 a 0.601b 46.05 ± 8.93 47.17 ± 9.38 45.12 ± 9.35 0.345a 0.843b 1.56 ± 0.25 1.73 ± 0.34 1.60 ± 0.28 0.062a 0.965b

Bassiouny EA, El-Samanoudy SI, Abbassi MM et al.. Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. Archives of Dermatological Research 2023, DOI 10.1007/s00403-022-02512-2. Citation sous licence CC-BY-4.0.

Trichoscopic Cetirizine + minoxidil group parameter (N = 26) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* Terminal hair 64.73 ± 15.63 67.71 ± 14.24 66.76 ± 13.44 0.355a percentage (%) Vellus hair per- 35.26 ± 15.63 32.28 ± 14.24 33.23 ± 13.44 0.355a centage (%) Terminal hair 97.62 ± 32.89 120.45 ± 36.73 177.43 ± 43.15 < 0.0005*a density/cm2 Vellus hair 52.77 ± 23.91 58.12 ± 28.29 90.98 ± 42.77 < 0.0005*a density/cm2 Terminal:vellus 2.84 ± 3.39 3.21 ± 3.46 2.99 ± 3.60 0.378 a Average 42.29 ± 10.06 43.91 ± 8.53 42.37 ± 7.97 0.217a thickness(µm) Average number 1.49 ± 0.22 1.68 ± 0.34 1.53 ± 0.21 0.007*a of hairs/ fol- licular unit * Level of significance P ˂ 0.05 a One-way RM-ANOVA (Time effect (t)) at P ˂ 0.05 b Mixed RM-ANOVA (time*group interaction (t × g)) at P ˂ 0.05 1 3 Archives of Dermatological Research (2023) 315:1293–1304 assessor (mean ranks: group 1 = 29.40 and N = 26, group

Citation complémentaire (significativite)

(N = 27) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* P-value (t × g)* 70.11 ± 12.99 70.25 ± 11.88 70.20 ± 12.05 0.998a 0.665b 29.88 ± 12.99 29.74 ± 11.88 29.79 ± 12.05 0.998a 0.665b 107.87 ± 28.63 133.44 ± 35.73 197.36 ± 43.07 < 0.0005*a 0.549b 46.92 ± 24.03 59.08 ± 35.73 85.90 ± 40.86 < 0.0005*a 0.724b 3.21 ± 2.31 3.02 ± 1.86 3.19 ± 2.54 0.916 a 0.601b 46.05 ± 8.93 47.17 ± 9.38 45.12 ± 9.35 0.345a 0.843b 1.56 ± 0.25 1.73 ± 0.34 1.60 ± 0.28 0.062a 0.965b

Bassiouny EA, El-Samanoudy SI, Abbassi MM et al.. Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. Archives of Dermatological Research 2023, DOI 10.1007/s00403-022-02512-2. Citation sous licence CC-BY-4.0.

(N = 27) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* P-value (t × g)* 70.11 ± 12.99 70.25 ± 11.88 70.20 ± 12.05 0.998a 0.665b 29.88 ± 12.99 29.74 ± 11.88 29.79 ± 12.05 0.998a 0.665b 107.87 ± 28.63 133.44 ± 35.73 197.36 ± 43.07 < 0.0005*a 0.549b 46.92 ± 24.03 59.08 ± 35.73 85.90 ± 40.86 < 0.0005*a 0.724b 3.21 ± 2.31 3.02 ± 1.86 3.19 ± 2.54 0.916 a 0.601b 46.05 ± 8.93 47.17 ± 9.38 45.12 ± 9.35 0.345a 0.843b

Citation complémentaire (significativite)

(N = 27) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* P-value (t × g)* 70.11 ± 12.99 70.25 ± 11.88 70.20 ± 12.05 0.998a 0.665b 29.88 ± 12.99 29.74 ± 11.88 29.79 ± 12.05 0.998a 0.665b 107.87 ± 28.63 133.44 ± 35.73 197.36 ± 43.07 < 0.0005*a 0.549b 46.92 ± 24.03 59.08 ± 35.73 85.90 ± 40.86 < 0.0005*a 0.724b 3.21 ± 2.31 3.02 ± 1.86 3.19 ± 2.54 0.916 a 0.601b 46.05 ± 8.93 47.17 ± 9.38 45.12 ± 9.35 0.345a 0.843b 1.56 ± 0.25 1.73 ± 0.34 1.60 ± 0.28 0.062a 0.965b

Bassiouny EA, El-Samanoudy SI, Abbassi MM et al.. Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. Archives of Dermatological Research 2023, DOI 10.1007/s00403-022-02512-2. Citation sous licence CC-BY-4.0.

Trichoscopic Cetirizine + minoxidil group parameter (N = 26) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* Terminal hair 64.73 ± 15.63 67.71 ± 14.24 66.76 ± 13.44 0.355a percentage (%) Vellus hair per- 35.26 ± 15.63 32.28 ± 14.24 33.23 ± 13.44 0.355a centage (%) Terminal hair 97.62 ± 32.89 120.45 ± 36.73 177.43 ± 43.15 < 0.0005*a density/cm2 Vellus hair 52.77 ± 23.91 58.12 ± 28.29 90.98 ± 42.77 < 0.0005*a density/cm2 Terminal:vellus 2.84 ± 3.39 3.21 ± 3.46 2.99 ± 3.60 0.378 a Average 42.29 ± 10.06 43.91 ± 8.53 42.37 ± 7.97 0.217a thickness(µm) Average number 1.49 ± 0.22 1.68 ± 0.34 1.53 ± 0.21 0.007*a of hairs/ fol- licular unit * Level of significance P ˂ 0.05 a One-way RM-ANOVA (Time effect (t)) at P ˂ 0.05 b Mixed RM-ANOVA (time*group interaction (t × g)) at P ˂ 0.05 1 3 Archives of Dermatological Research (2023) 315:1293–1304 assessor (mean ranks: group 1 = 29.40 and N = 26, group

Citation complémentaire (significativite)

(N = 27) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* P-value (t × g)* 70.11 ± 12.99 70.25 ± 11.88 70.20 ± 12.05 0.998a 0.665b 29.88 ± 12.99 29.74 ± 11.88 29.79 ± 12.05 0.998a 0.665b 107.87 ± 28.63 133.44 ± 35.73 197.36 ± 43.07 < 0.0005*a 0.549b 46.92 ± 24.03 59.08 ± 35.73 85.90 ± 40.86 < 0.0005*a 0.724b 3.21 ± 2.31 3.02 ± 1.86 3.19 ± 2.54 0.916 a 0.601b 46.05 ± 8.93 47.17 ± 9.38 45.12 ± 9.35 0.345a 0.843b 1.56 ± 0.25 1.73 ± 0.34 1.60 ± 0.28 0.062a 0.965b

Bassiouny EA, El-Samanoudy SI, Abbassi MM et al.. Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. Archives of Dermatological Research 2023, DOI 10.1007/s00403-022-02512-2. Citation sous licence CC-BY-4.0.

(N = 27) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* P-value (t × g)* 70.11 ± 12.99 70.25 ± 11.88 70.20 ± 12.05 0.998a 0.665b 29.88 ± 12.99 29.74 ± 11.88 29.79 ± 12.05 0.998a 0.665b 107.87 ± 28.63 133.44 ± 35.73 197.36 ± 43.07 < 0.0005*a 0.549b 46.92 ± 24.03 59.08 ± 35.73 85.90 ± 40.86 < 0.0005*a 0.724b 3.21 ± 2.31 3.02 ± 1.86 3.19 ± 2.54 0.916 a 0.601b 46.05 ± 8.93 47.17 ± 9.38 45.12 ± 9.35 0.345a 0.843b

Citation complémentaire (significativite)

(N = 27) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* P-value (t × g)* 70.11 ± 12.99 70.25 ± 11.88 70.20 ± 12.05 0.998a 0.665b 29.88 ± 12.99 29.74 ± 11.88 29.79 ± 12.05 0.998a 0.665b 107.87 ± 28.63 133.44 ± 35.73 197.36 ± 43.07 < 0.0005*a 0.549b 46.92 ± 24.03 59.08 ± 35.73 85.90 ± 40.86 < 0.0005*a 0.724b 3.21 ± 2.31 3.02 ± 1.86 3.19 ± 2.54 0.916 a 0.601b 46.05 ± 8.93 47.17 ± 9.38 45.12 ± 9.35 0.345a 0.843b 1.56 ± 0.25 1.73 ± 0.34 1.60 ± 0.28 0.062a 0.965b

Bassiouny EA, El-Samanoudy SI, Abbassi MM et al.. Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. Archives of Dermatological Research 2023, DOI 10.1007/s00403-022-02512-2. Citation sous licence CC-BY-4.0.

Trichoscopic Cetirizine + minoxidil group parameter (N = 26) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* Terminal hair 64.73 ± 15.63 67.71 ± 14.24 66.76 ± 13.44 0.355a percentage (%) Vellus hair per- 35.26 ± 15.63 32.28 ± 14.24 33.23 ± 13.44 0.355a centage (%) Terminal hair 97.62 ± 32.89 120.45 ± 36.73 177.43 ± 43.15 < 0.0005*a density/cm2 Vellus hair 52.77 ± 23.91 58.12 ± 28.29 90.98 ± 42.77 < 0.0005*a density/cm2 Terminal:vellus 2.84 ± 3.39 3.21 ± 3.46 2.99 ± 3.60 0.378 a Average 42.29 ± 10.06 43.91 ± 8.53 42.37 ± 7.97 0.217a thickness(µm) Average number 1.49 ± 0.22 1.68 ± 0.34 1.53 ± 0.21 0.007*a of hairs/ fol- licular unit * Level of significance P ˂ 0.05 a One-way RM-ANOVA (Time effect (t)) at P ˂ 0.05 b Mixed RM-ANOVA (time*group interaction (t × g)) at P ˂ 0.05 1 3 Archives of Dermatological Research (2023) 315:1293–1304 assessor (mean ranks: group 1 = 29.40 and N = 26, group

Citation complémentaire (significativite)

(N = 27) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* P-value (t × g)* 70.11 ± 12.99 70.25 ± 11.88 70.20 ± 12.05 0.998a 0.665b 29.88 ± 12.99 29.74 ± 11.88 29.79 ± 12.05 0.998a 0.665b 107.87 ± 28.63 133.44 ± 35.73 197.36 ± 43.07 < 0.0005*a 0.549b 46.92 ± 24.03 59.08 ± 35.73 85.90 ± 40.86 < 0.0005*a 0.724b 3.21 ± 2.31 3.02 ± 1.86 3.19 ± 2.54 0.916 a 0.601b 46.05 ± 8.93 47.17 ± 9.38 45.12 ± 9.35 0.345a 0.843b 1.56 ± 0.25 1.73 ± 0.34 1.60 ± 0.28 0.062a 0.965b

Bassiouny EA, El-Samanoudy SI, Abbassi MM et al.. Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. Archives of Dermatological Research 2023, DOI 10.1007/s00403-022-02512-2. Citation sous licence CC-BY-4.0.

(N = 27) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* P-value (t × g)* 70.11 ± 12.99 70.25 ± 11.88 70.20 ± 12.05 0.998a 0.665b 29.88 ± 12.99 29.74 ± 11.88 29.79 ± 12.05 0.998a 0.665b 107.87 ± 28.63 133.44 ± 35.73 197.36 ± 43.07 < 0.0005*a 0.549b 46.92 ± 24.03 59.08 ± 35.73 85.90 ± 40.86 < 0.0005*a 0.724b 3.21 ± 2.31 3.02 ± 1.86 3.19 ± 2.54 0.916 a 0.601b 46.05 ± 8.93 47.17 ± 9.38 45.12 ± 9.35 0.345a 0.843b

Citation complémentaire (significativite)

(N = 27) Mean ± SD Baseline 12 weeks 24 weeks P-value (t)* P-value (t × g)* 70.11 ± 12.99 70.25 ± 11.88 70.20 ± 12.05 0.998a 0.665b 29.88 ± 12.99 29.74 ± 11.88 29.79 ± 12.05 0.998a 0.665b 107.87 ± 28.63 133.44 ± 35.73 197.36 ± 43.07 < 0.0005*a 0.549b 46.92 ± 24.03 59.08 ± 35.73 85.90 ± 40.86 < 0.0005*a 0.724b 3.21 ± 2.31 3.02 ± 1.86 3.19 ± 2.54 0.916 a 0.601b 46.05 ± 8.93 47.17 ± 9.38 45.12 ± 9.35 0.345a 0.843b 1.56 ± 0.25 1.73 ± 0.34 1.60 ± 0.28 0.062a 0.965b

Bassiouny EA, El-Samanoudy SI, Abbassi MM et al.. Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. Archives of Dermatological Research 2023, DOI 10.1007/s00403-022-02512-2. Citation sous licence CC-BY-4.0.